CS
ITCI

Credit Suisse’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Credit Suisse’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$8.62M Buy
124,596
+6,014
+5% +$413K 0.01% 993
2023
Q4 		$8.49M Buy
118,582
+6,474
+6% +$372K 0.01% 1015
2023
Q3 		$5.84M Sell
112,108
-4,243
-4% -$247K 0.01% 1180
2023
Q2 		$7.37M Buy
116,351
+7,589
+7% +$473K 0.01% 1080
2023
Q1 		$5.89M Buy
108,762
+3,589
+3% +$174K 0.01% 1200
2022
Q4 		$5.57M Buy
105,173
+27,779
+36% +$1.39M 0.01% 1238
2022
Q3 		$3.6M Buy
77,394
+3,599
+5% +$188K ﹤0.01% 1458
2022
Q2 		$4.21M Sell
73,795
-416
-0.6% -$23.6K ﹤0.01% 1401
2022
Q1 		$4.54M Buy
74,211
+17,682
+31% +$918K ﹤0.01% 1525
2021
Q4 		$2.96M Sell
56,529
-244,561
-81% -$10.3M ﹤0.01% 2457
2021
Q3 		$11.2M Buy
301,090
+253,384
+531% +$8.81M 0.01% 1465
2021
Q2 		$1.95M Sell
47,706
-4,393
-8% -$162K ﹤0.01% 2889
2021
Q1 		$1.77M Sell
52,099
-37,173
-42% -$1.29M ﹤0.01% 2910
2020
Q4 		$2.84M Buy
89,272
+34,680
+64% +$911K ﹤0.01% 2568
2020
Q3 		$1.4M Sell
54,592
-6,708
-11% -$153K ﹤0.01% 2696
2020
Q2 		$1.57M Sell
61,300
-84,934
-58% -$1.72M ﹤0.01% 2571
2020
Q1 		$2.25M Buy
146,234
+121,436
+490% +$2.64M ﹤0.01% 2060
2019
Q4 		$851K Sell
24,798
-8,405
-25% -$101K ﹤0.01% 3244
2019
Q3 		$248K Buy
33,203
+11,016
+50% +$106K ﹤0.01% 3779
2019
Q2 		$287K Sell
22,187
-771
-3% -$9.89K ﹤0.01% 3702
2019
Q1 		$280K Buy
22,958
+504
+2% +$6.44K ﹤0.01% 3627
2018
Q4 		$256K Buy
22,454
+577
+3% +$9.31K ﹤0.01% 3585
2018
Q3 		$474K Sell
21,877
-8,819
-29% -$184K ﹤0.01% 3332
2018
Q2 		$542K Sell
30,696
-5,582
-15% -$113K ﹤0.01% 3383
2018
Q1 		$763K Sell
36,278
-3,473
-9% -$67.7K ﹤0.01% 3141
2017
Q4 		$576K Buy
39,751
+966
+2% +$14.9K ﹤0.01% 3359
2017
Q3 		$612K Buy
38,785
+20,905
+117% +$307K ﹤0.01% 3422
2017
Q2 		$222K Sell
17,880
-3,091
-15% -$35.8K ﹤0.01% 3587
2017
Q1 		$341K Sell
20,971
-15,605
-43% -$226K ﹤0.01% 3475
2016
Q4 		$551K Buy
36,576
+8,575
+31% +$121K ﹤0.01% 3388
2016
Q3 		$426K Buy
28,001
+1,058
+4% +$42.8K ﹤0.01% 3502
2016
Q2 		$1.05M Buy
26,943
+1,828
+7% +$65.7K ﹤0.01% 2882
2016
Q1 		$697K Buy
25,115
+14,533
+137% +$484K ﹤0.01% 3002
2015
Q4 		$569K Sell
10,582
-4,711
-31% -$238K ﹤0.01% 3274
2015
Q3 		$612K Buy
15,293
+2,164
+16% +$70.6K ﹤0.01% 3253
2015
Q2 		$419K Sell
13,129
-34,665
-73% -$879K ﹤0.01% 3835
2015
Q1 		$1.14M Buy
+47,794
New +$1.07M ﹤0.01% 2862
2014
Q3 		– Sell
-20,427
Closed -$344K – 4686
2014
Q2 		$344K Sell
20,427
-15,873
-44% -$262K ﹤0.01% 4034
2014
Q1 		$660K Buy
+36,300
New +$655K ﹤0.01% 3504

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Credit Suisse's ITCI Position: Q1 2024 in Review

Credit Suisse increased its Intra-Cellular Therapies Inc. (ITCI) stake by 5.1% in Q1 2024, buying an estimated $413K and bringing the position to 124,596 shares worth $8.62M. The position accounts for 0.01% of the portfolio, ranked #993.

Credit Suisse first reported a position in ITCI in Q1 2014 and has held it in 39 quarters since. The position peaked at $11.2M in Q3 2021. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Credit Suisse held 124,596 shares of Intra-Cellular Therapies Inc. worth $8.62M as of Q1 2024.
  • Credit Suisse bought 6,014 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $413K.
  • Intra-Cellular Therapies Inc. made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #993 holding.
  • Credit Suisse first reported a position in Intra-Cellular Therapies Inc. in Q1 2014 and has held it in 39 quarters since.
  • Credit Suisse's Intra-Cellular Therapies Inc. position peaked at $11.2M in Q3 2021.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.